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The prognostic value of different factors upon diagnosis of CML was analysed in 45 Philadelphia (Ph1)-positive patients. The median
survival was 48 months. Univariate analysis showed 5 poor prognostic factors (male sex, under 45 years-old, bone marrow blasts
greater than or equal to 10 percent, blood basophils greater than or equal to 6 percent and blood eosinophils greater than or equal to
6 percent) which provided for the development of a clinical staging system: Stage I with none or one factor and a two-year survival rate
of 100 percent; Stage II with two or three factors and two-year survival of 72.2 percent; and Stage III with four or five factors and two-
year survival of 0 percent (p = 0.00016). Multivariate survival analysis showed that combination of blood basophilia and bone marrow
blasts had the strongest predictive relationship to survival time. We conclude that a combination of pretreatment factors identifies
different risk subcategories in CML patients and is helpful in assessing the overall prognosis and the treatment approach.
UNITERMS: Chronic Myeloid Leukemia. Philadelphia Chromosome. Prognosis.
INTRODUCTION OBJECTIVE
The analysis of prognostic factors has allowed forthe elaboration of staging systems in order to planfor the treatment2.17 of several hematologic diseases.
In CML, these studies have been used to guide the best
therapeutic approach in each case, such as bone marrow
transplantation, which should be implemented as soon as
possible during the chronic phase in young patients with a
compatible donor.
This study seeks to analyze the prognostic
significance of different features detected at diagnosis in
a series of CML patients from a public Brazilian hospital,
in order to determine if the prognostic factors of this
population were different from well-established factors
detected in studies performed in other countries.
MATERIAL AND METHODS
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We are reporting on the analysis of 45 adult Ph 1-
positive CML patients in the chronic phase who were
admitted to our hospital between September 1977 and
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There were 25 (55.6 percent) males and 20 (44.4
percent) females. The median age was 42 (ranging from
15-77). There were 25 (55.6 percent) white patients, 18
(40.0 percent) were black, and 2 (4.4 percent) were Asian.
The median survival was 48 months (Fig. I). At the time
the analysis was conducted in May 1993, 15 (33.4 percent)
patients had died, 23 (51.1 percent) were alive and 7 (15.5
percent) had discontinued follow-up some time after
diagnosis. Of the 23 living patients, 18 (78.3 percent) were
in the chronic phase, 3 (13.0 percent) in the accelerated
phase, and 2 (8.7 percent) were alive after blastic phase.
RESULTS
Kaplan and Meyer's method'2. Different curves were
statistically compared using the Cox-Mantel (log rank)
or the generalized W,ilcoxon Test13• The staging system
was derived from univariate analysis using the variables
associated with bad prognosis. Thus, the low-risk or
Stage I group consisted of patients with zero or one
factor; the intermediate-risk group or Stage II consisted
of 2 or 3 factors and the high-risk group, 4 or 5 factors.
Using the Cox model4, we performed a multivariate
analysis of all variables previously selected by
univariate analysis, which were then put into a single
equation to determine the variable~ which were
primarily important to prognosis and those which were
only secondary factors.
Figure 1 - General survival of 45 CML Ph1-positive patients.
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January 1993. The follow-up period varied from 1 to
184 months. There were 7 (15.5 percent) patients with
a follow-up of less than 1 year, and 3 (6.7 percent) with
less than 6 months. The diagnosis of CML was based
on conventional criteria. The karyot~pe was evaluated
by usual methods with G banding and classified
according to ISCN (1985, 1991). The characterization
of blast crisis was made from the analysis of bone
marrow aspiration (more than 30 percent of blasts), and
the type of crisis was determined by cytochemistry and
immunophenotyping methods. Patients in the chronic
or accelerated phase were treated with busulfan or
hydroxyurea. Lymphoid blast crisis was treated with
vincristine, daunorubicin and prednisone, and myeloid
blast crisis with daunorubicin and cytosine arabinoside,
until patients returned to the chronic phase when
busulfan or hydroxyurea was restarted. At diagnosis,
the following clinical and hematological data were
recorded and evaluated for prognosis: 1) age, sex, race,
spleen and liver size; 2) peripheral blood features:
hemoglobin concentration (Hb), platelet counts, white
blood cell counts (WBC) with differential counts; and
blood erythroblast percentage; 3) bone marrow
aspiration features: blast cells percentage and myeloid/
erythroid (M/E) ratio; 4) bone marrow biopsy features:
granulocytic proliferation (Gran) or granulocytic plus
megakaryocytic proliferation (Gran/Meg), eosinophilia,
presence of blast cells, fibrosis and megakaryocyte
morphology 10. For patients who discontinued follow-
up sometime during this study, the survival period was
defined as the date when the patient was last seen; for
patients who died, the survival
period was defined as the date
of death; for patients who were
alive in May 1993, the survival
period was considered to be until
that date.
For univariate analysis, the
cut-off level of each quantitative
variable was established based
on those commonly found in the
literature data. In some cases,
this was established by chance,
until "p" values near 5 percent
were found. The different
categories of qualitative
~variables, such as sex, race and 0
bone marrow histology, were
compared to each other.
Actuarial survival probability
curves were plotted according to
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OBS: N = number of patients; * = pO.OS; Hb = hemoglobin; BM =
bone marrow; M/E = myeloid/erythroid
Table 1
Results of the univariate analysis
BM BLASTS
Factor N
SEX male
female
AGE <45 yr
>=45yr
<60 yr
>=60yr
RACE white
black
SPLEENO-10 cm
> 10 cm
LIVER normal
enlarged
Hb(FEMALE) < 12g%
>=12g%
Hb(MALE) < 13g%
>=13g%
WBC < 1OOX109/1
>=100X109/1
PLATELET < 400X1 09/1
>=400X109/1
150<x<500X109/1
<150 or >500
ERYTHROBLASTS 0%
>0%
PERIPHERAL BLASTS 0 - 1
> 1
<5%
>=5%
<10%
>=10%
< 10%
>=10%
BLOOD BASOPHILS < 6%
>=6%
BLOOD EOSINOPHILS < 6%
>=6%
M/E RATIO <20
>=20
<30
>=30
BM GRAN
GRAN/MEG
FIBROSIS 0/+
++/+++
P
25
20
24
21
33
12
25
18
19
23
17
26
15
04
23
00
16
26
27
14
11
30
34
11
22
20
35
07
40
02
38
02
32
12
32
10
17
15
22
10
12
16
09
19
0.04664*
0.00783*
0.26745
0.73522
0.07330
0.52875
0.63783
0.39870
0.15681
0.88121
0.39574
0.56602
0.77335
0.27416
0.00121'
0.00010'
0.02938'
0.70445
0.64397
0.74759
0.42116
Amongst all the patients, the number of blast crises was
16, with 2 (12.5 percent) patients still alive and 14 (87.5
percent) dead. There were 6 (37.5 percent) lymphoid blast
crises, 9 (56.3 percent) myeloid blast crises and I (6.2
percent) unclassified. The mean survival of all blast crises
was 4.5 months, with 6.2 months for lymphoid and 4.1
months for myeloid, but this difference was not significant
(p = 0.22285). Death was due to blastic transformation in
14 (93.3 percent) cases, and in 1 patient (6.7 percent), to
other complications. The univariate analysis demonstrated
5 variables that seemed to be associated with poor
prognosis (p < 0.05): male sex (p = 0.04664), aged < 45
(p = 0.00783); bone marrow blasts greater than or equal
to 10 percent (p = 0.00 12l); blood basophils greater than
or equal to 6 percent (p = 0.00010); and blood eosinophi Is
greater than or equal to 6 percent (p = 0.02938). The other
variables, such as spleen size, liver size, hemoglobin level,
white blood cell counts, platelet counts, peripheral blasts,
circulating erythroblasts, M/E ratio and bone marrow
features (Gran or Gran/Meg and fibrosis), were not
statistically significant at the different cut-off levels tested
(Table 1).
The staging system, derived from the univariate
analysis, permitted the population to be divided into 3
groups: Stage I with 19 (42.2 percent) patients, Stage II
with 16 (35.5 percent) and Stage III with 4 (8.8 percent).
Six (13.3 percent) patients were excluded due to lack of
data on one or more selected variables. The death rate
was 0.0 percent (0/l9) for Stage 1,37.5 percent (6/16) for
Stage II, and 75.5 percent (3/4) for Stage III, and this
difference was significant (p = 0.00016) (Fig. 2).
Multivariate analysis was performed on 38 patients who
had data for 5 variables selected by univariate analysis
and 4 variables of prognostic importance (hemoglobin,
spleen, platelet counts and peripheral blast cells). Only
two variables were identified as primarily important for
prognosis: blood basophils (p = 0.004) and bone marrow
blasts (p = 0.042). The equation derived from multivariate
analysis was:
RR= EXP{0.2936 (BM BL - 2.58) + 0.2647
(PB BASO - 4.21)}
RR = relative risk; BM BL = % bone marrow blasts; PB BASO =
% peripheral blood basophils; 2.58 = mean of bone marrow blasts
(%); 4.21 = mean of blood basophils (%).
Using this analysis, patients were divided into 3
groups: low relative risk (RR) « 1.0); intermediate RR
(1.0 to 10.0); and high RR (> 10.0. The Wilcoxon test
showed that there was a significant difference of survival
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important, because patients under 45 years-
old are those referred for bone marrow
transplantation. Unfortunately, the
multivariate analysis did not confirm age as
an important prognostic factor, perhaps due
to the small number of patients in this study.
As described by others2.10.11, bone marrow
blasts of 10 percent or more was another
finding negatively related to survival in our
population (p = 0.00121), which might be
associated with an early accelerated phase.
Marked peripheral basophilia at diagnosis
was described as a poor prognostic
factors.,o.'1.'9, and was another significant
negative factor in our study (6 percent or
more) (p = 0.000 I0). Along the same line,
eosinophilia which is or is not associated with
basophilia has been related to a bad
prognosiss.'7.'s, as shown in this report (p = 0.02938).
Other factors tested in this study such as spleen and liver
size, white blood cell counts, platelet counts, peripheral
blast cells, blood erythroblasts, M/E ratio and bone
marrow aspects (Gran or Gran/Meg and fibrosis) did not
significantly affect the prognosis in our population. Some
authors have described enlarged spleen2.,o.'I.'lUO or
liver2.'1.20, low hemoglobin 10.11,increased leukocyte
countsS.19, low or high platelet countsIO.II.20, high
percentages of blasts in peripheral bloods.'lI.2O,presence
of erythroblasts in peripheral blood2.'7, high lactic
dehidrogenase levels.17, high uric acid and an increased
M/E ratioS as unfavorable factors at diagnosis. SaKAL
et al.ls reported an actuarial death rate of 5-1 0 percent in
MONTHS
stage I
o
o
100
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Figure 3 - Survival of patients with low, intermediate and high relative
risk (RR), according to the equation derived from multivariate analysis
(p = 0.00000).
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DISCUSSION
in the 3 groups (p = 0.00000) (Fig. 3). The actuarial death
rate; 5.1 percent during the first year after dignosis, 18.1
percent during the second, 23.1 percent during the third,
and 18.2 percent during the fourth, achieved a "plateau"
after the fifth year.
Figure 2 - Actuarial survival probability curves of Stages 1,'11and III, according
to the proposed staging system (p = 0.00016).
The fatal outcome of CML has stimulated the analysis
of prognostic factors. However, besides the absence of
the Ph 1 chromosome, which leads to a rapid evolution to
the blastic phase2.6.S.IO.17.IS,there is no agreement as to the
prognostic importance of the many different
features at diagnosis.
The median age of 42 in this study was
lower than expected's. The median survival of ~
48 months was in accordance with other 80
authors2.S.IO.16.There was no difference between ~
survival and death rates after the onset of blast ~ 60
crises, although lymphoid blast crises seemed ~
to be more responsi ve to conventional ~ 40
chemotherapy9. Male sex, as described by other .J
authors Ill.17,and age under 45 were associated ~
with an unfavorable prognosis (p =,0.04664 and ~ 20
0.00783, respectively) in our study. In a ~
o
worldwide multicentric study, SaKAL et al.ls
described age as a factor with a progressively
unfavorable prognosis at higher values:
Therefore, this is the first significant
difference between our population and others
previously studied. This aspect seems highly
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Table 2
Number, initials, sex, age (in years), race, spleen size (left rib edge, in centimeters), liver size (right rib edge, in
centimeters), % of hemoglobin (Hb), number of white blood cells (WBC) per cubic millimeter, platelets (per cubic
millimeter) and erythroblasts (Erythro) in the peripheral blood of the 45 patients.
Number Initials Sex Age Race Spleen Liver Hb. WBC Platelets Erythro
1 ADA M 36 W 20 0 12 25100 750000 0
2 AFN M 36 W 25 5 6 3200 45000 14
3 AS M 57 W 5 2 6 140000 126000 0
4 AMMF M 17 B 30 0 7 36000 200000 0
5 AAA F 25 B 12 0 10 170000 350000 0
6 BAA F 15 B 7 2 7 240000 360000 0
7 CMMP F 72 W 7 0 10 77300 332000 0
8 CSM F 38 B 25 2 11 96000 380000 0
9 CVS M 56 B 15 1 13 140000 450000 8
10 CL F 16 B 15 2 9 502000 730000 0
11 EV M 57 W 6 0 12 141000 350000 0
12 EON M 62 W 8 0 11 68000 150000 0
13 ESC F 42 W 8 3 12 126800 300000 3
14 ERC F 64 W 25 0 6 700000 200000 4
15 FLJ M 33 B 0 1 9 214000 160000 0
16 FBL F 33 W 20 0 11 400000 240000 1
17 GC M 64 W 7 5 7 37000 140000 3
18 HMA F 53 W 20 3 11 150000 210000 3
19 JAS M 39 B 15 0 12 84000 IGN 0
20 JMG M 30 W 10 2 12 156000 400000 0
21 JNPF M 62 W 15 3 9 176000 600000 0
22 JDJT M 27 W 20 0 7 560000 150000 0
23 LE M 61 W 20 0 10 190000 260000 0
24 LAS M 36 W 20 4 IGN IGN IGN 0
25 LCNF M 31 B 10 2 13 122000 260000 1
26 LRP M 25 W 16 4 11 80000 470000 1
27 MSA M 27 W 23 4 7 280000 200000 0
28 MRC M 21 W 18 4 9 192000 500000 0
29 MACA F 46 B 5 4 11 13500 1000000 2
30 MLNH F 58 W 10 0 11 180900 350000 0
31 MHS F 51 W 3 3 12 48000 420000 0
32 MCS M 26 B 6 0 8 73000 260000 0
33 NP F 70 W 1 0 11 15500 282000 0
34 aT F 58 W 10 3 11 15400 350000 0
35 PBB M 62 W 25 2 11 132900 777000 0
36 PS F 69 W 12 4 9 276000 595000 0
37 RTY M 30 A IGN IGN IGN IGN IGN 0
38 STM F 32 B 16 6 9 205800 450000 0
39 YM M 77 A 4 4 11 58300 110000 0
40 MSS F 65 B 20 0 10 142000 160000 6
41 MCC F 42 B 0 0 12 80000 240000 0
42 LGNS M 27 B 10 0 10 348000 190000 0
43 JFS F 64 B IGN 12 16 100000 450000 0
44 EGFR F 34 B IGN IGN IGN IGN IGN 0
45 JFC M 47 B 30 8 7 700000 550000 0
Legend: M = Male; F = Female; W = White; B = Black; A = Asian; IGN = ignored
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Table 3
Patient number (N), % of blasts (BLAST), promyelocyte (PM) and myelocyte (M) in the peripheral blood, % of blasts in
the bone marrow (BMB), % of eosinophils (EOSI) and basophils (BASO) in the peripheral blood, bone marrow M/E
ratio (MlE), overall survival (OS) in months, post blast crisis survival (PBCS) in months, bone marrow biopsy
classification (BMC), degree of fibrosis in bone marrow (FIBRO), score (SCORE) and relative risk (RR)
NQ BLAST PM M BMB EOSI BASO M/E OS PBCS BMC FIBRO SCORE RR
1 0 0 0 7 2 0 IGN 10 NC IGN IGN II 1,20
2 0 3 0 5 27 4 10 27 NC G + II 1,93
3 2 1 3 5 6 7 13 36 4 G+M ++ II 4,27
4 4 5 15 3 1 8 75 31 10 G+M +++ II 3,09
5 2 0 29 0 0 0 8 13 NC G+M ++ II 0,15
6 4 0 9 0 2 2 12 13 NC G + I 0,26
7 4 8 4 0 5 0 IGN 30 NC IGN IGN I 0,15
8 2 5 16 0 5 3 IGN 12 NC G+M ++ I 0,34
9 2 2 20 0 3 4 5 16 NC G+M + I 0,44
10 5 3 40 1 1 3 IGN 48 NC G 0 I 0,46
11 3 5 5 1 4 0 19 39 NC G ++ I 0,21
12 5 14 15 1 4 4 13 97 NC G+M + I 0,60
13 14 29 30 5 7 0 11 59 3 G 0 II 0,67
14 5 6 30 IGN 4 2 IGN 1 NC IGN IGN IGN IGN
15 0 0 0 2 4 0 10 33 8 IGN IGN II 0,28
16 1 8 12 0 3 7 9 24 NC IGN IGN II 0,98
17 0 6 6 IGN 0 0 IGN 48 NC IGN IGN IGN IGN
18 28 2 5 3 1 2 100 35 NC G+M +++ I 0,63
19 8 1 2 12 7 3 11 24 4 G ++ III IGN
20 0 5 13 10 3 10 9 10 1 IGN IGN III 41,00
21 2 1 3 0 2 10 6 34 3 G+M +++ II 2,10
22 5 2 4 5 5 12 30 10 5 G ++ II 16,00
23 0 0 0 1 22 4 50 13 NC G+M ++ II 0,60
24 IGN IGN IGN IGN IGN IGN IGN 18 7 IGN IGN IGN IGN
25 0 0 0 1 0 1 IGN 11 NC G + II 0,20
26 0 0 6 0 8 10 32 16 4 G+M + III 2,10
27 0 25 3 0 21 26 55 14 NC G + III 150,30
28 0 0 2 1 7 0 23 15 NC G+M ++ II 0,20
29 0 0 1 1 1 5 IGN 66 NC G+M +++ I 0,70
30 0 4 6 1 0 0 39 35 NC G+M ++ I 0,20
31 0 0 7 0 1 1 18 18 NC IGN IGN , 0,20
32 2 0 5 IGN 1 8 IGN 33 1 IGN IGN IGN IGN
33 0 1 1 0 2 2 IGN 73 NC IGN IGN I 0,20
34 0 1 2 0 4 4 6 184 NC IGN IGN I 0,44
35 1 1 8 8 4 0 21 78 NC G+M ++ I 1,62
36 4 2 3 2 8 6 20 19 1 G +++ II 1,36
37 IGN IGN IGN IGN IGN IGN IGN 42 1 IGN IGN IGN IGN
38 4 10 9 5 11 11 31 17 6 IGN IGN II 12,38
39 2 0 3 3 0 2 48 68 NC G ++ I 0,63
. 40 0 0 1 2 4 0 24 7 NC G ++ I 0,28
41 0 0 2 1 3 1 22 5 NC IGN IGN I 0,27
42 0 5 14 6 4 1 IGN 5 NC G+M +++ II 1,17
43 0 0 0 0 2 0 17 7 NC G+M +++ I 0,15
44 IGN 0 0 7 IGN IGN 36 64 10 IGN IGN IGN IGN
45 0 0 0 4 4 14 10 9 NC IGN IGN II 20,31
Legend: NC = No blastic crisis; IGN = Ignored
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a Ph I-positive population during the first year after
diagnosis, and 23-28 percent per year during the third to .
the fifth year. In another study20, the rates were 5 percent
during the first year after diagnosis, 12 percent during
the second and 22,5 percent per year during the next eight
years. Our data is compatible: 5.1 percent in the first year,
18.1 percent in the second, 23.1 percent in the third, 18.2
percent in the fourth, and a "plateau" after the fifth year.
The staging system proposed here permits our population
to be divided into three distinct groups: low, intermediate
and high risk, with significant differences between mean
survi vals and death rates. Along the same line, the
multivariate analysis permitted the population to be
divided into 3 groups (low, intermediate and high risk
groups) with significant difference in survival (p =
0.00000) which we believe is more accurate than the
proposed staging system, which provides an equation that
only includes prognostic factors with primary importance.
CONCLUSIONS
We conclude that there is the possibility of identifying
some high-risk factors in a CML population with the aim
of recognizing patients at a high risk of acceleration so as
to schedule bone marrow transplantation as soon as
possible. Further studies should be carried out in order to
identify other poor prognostic factors in the CML Brazilian
population, and to investigate the reason for high death
rates among younger patients.
RESUMO
Avaliamos 0 valor progn6stico de diferentes fatores, ao diagn6stico, em 45 pacientes com LMC Ph1-positivos. A sobrevida
mediana foi de 48 meses. A analise univariada identificou 5 fatores associ ados a pior progn6stico (sexo masculino, idade
inferior a 45 anos, blastos na medula 6ssea maior ou igual a 10 percent, bas6filos no sangue periferico maior ou igual a 6
percent e eosin6filos no sangue periferico maior ou igual a 6 percent), originando um sistema de estadiamento: estagio I com
zero ou um fator e sobrevida de 100 percent em dois anos; estagio II com dois ou tres fatores e sobrevida de 72,2 percent em
dois anos; estagio III com 4 ou 5 fatores e sobrevida de 0 percent em dois anos (p = 0.00016). A analise multivariada demonstrou
que a basofilia no sangue periferico e os blastos na medula 6ssea foram os fatores que melhor se correlacionaram com 0
tempo de sobrevida. Conclufmos que a combinay60 de fatores presentes no diagn6stico permite a identificayao de diferentes
grupos de risco na LMC, podendo ser util na determinay60 do progn6stico e na abordagem terapeutica .
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